Auro reported 7% YoY increase in net sales in Q2FY19 aided by growth in the US (up 6% YoY), ARV (up 18% YoY) and RoW business (up 26.3% YoY). Formulations business registered 7% YoY growth in Q2FY19 led by US business which grew 6% YoY despite high base in the corresponding quarter due to gRenvela exclusivity. The growth in the US was driven by currency benefits, new product launches in both oral and injectable segments and volume growth in existing products. The company filed 25 ANDAs, launched 14 products including 2 injectables in the quarter and received final approval for 13 ANDAs and tentative approval for two ANDAs in Q2FY19. On a cumulative basis, Auro filed 510 ANDAs with USFDA and received 385 approvals. AuroMedics, the injectable business witnessed a growth of 8% YoY driven by Ertapenem launch and the management has maintained its...